Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Neuro Reflection

A Neuro Reflection As mortality rates decline, the global burden of neurological disease is on the rise. Stroke affects 15 million people worldwide each year, contributing to 5 million deaths and another 5 million left with permanent disability (Vos et al., 2017). By 2050, the rate of dementia is expected to triple to 115 million worldwide (Prince et al ., 2013). Over the last twenty years, we have seen dramatic advances in the treatment of neurological disease. The National Institute of Neurological Disease (NINDs) trial that tested t-PA opened the door for successful treatment of acute stroke reducing death and disability (Koroshtez, 1996). In 2015, the results of five trials that evaluated endovascular treatments showed the profound benefit of early removal of thrombus in anterior circulation strokes (Goyal et al., 2016). Lessons from Finland taught us to reorganize our care, bypassing the red tape of “checking in patients” to adopt a “door to CT” approach that substantially reduced “door to needle” times and improved outcome (Lindsberg et al., 2006). In developed countries, medical progress has promoted the growth of specialized care units and tailored treatment for stroke, traumatic brain injury, dementia and Parkinson’s disease. These advances have opened the door for dedicated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Australasian Journal of Neuroscience de Gruyter

A Neuro Reflection

Download PDF
2 pages

Loading next page...
 
/lp/de-gruyter/a-neuro-reflection-dXurdPlrlS
Publisher
de Gruyter
Copyright
© 2020 Christi DeLemos et al., published by Sciendo
eISSN
2208-6781
DOI
10.21307/ajon-2020-001b
Publisher site
See Article on Publisher Site

Abstract

As mortality rates decline, the global burden of neurological disease is on the rise. Stroke affects 15 million people worldwide each year, contributing to 5 million deaths and another 5 million left with permanent disability (Vos et al., 2017). By 2050, the rate of dementia is expected to triple to 115 million worldwide (Prince et al ., 2013). Over the last twenty years, we have seen dramatic advances in the treatment of neurological disease. The National Institute of Neurological Disease (NINDs) trial that tested t-PA opened the door for successful treatment of acute stroke reducing death and disability (Koroshtez, 1996). In 2015, the results of five trials that evaluated endovascular treatments showed the profound benefit of early removal of thrombus in anterior circulation strokes (Goyal et al., 2016). Lessons from Finland taught us to reorganize our care, bypassing the red tape of “checking in patients” to adopt a “door to CT” approach that substantially reduced “door to needle” times and improved outcome (Lindsberg et al., 2006). In developed countries, medical progress has promoted the growth of specialized care units and tailored treatment for stroke, traumatic brain injury, dementia and Parkinson’s disease. These advances have opened the door for dedicated

Journal

Australasian Journal of Neuroscience – de Gruyter

Published: May 1, 2020

There are no references for this article.